| CNS Pharmaceuticals is a clinical pharmaceutical company. Co. focuses on the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. Co.'s primary focus is on the development and testing of Berubicin, a development stage anthracycline intended to treat glioblastoma. Berubicin intercalates into deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. The CNSP average annual return since 2019 is shown above.
The Average Annual Return on the CNSP average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CNSP average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CNSP average annual return calculation with any dividends reinvested as applicable (on ex-dates).